home | news | 2012

CPDR Presentations and Highlights at the 2012 AUA Annual Meeting in Atlanta, GA; May 19-23


June 8, 2012

In addition to Dr. Rosen's and Dr. Allemang's winning poster presentations, the CPDR multi-disciplinary team presented 9 other notable, moderated poster presentations at the 2012 AUA Annual Meeting. This showing – 11 presentations total – from the CPDR team is one of the largest in recent history, and the directors and staff are extremely proud of the hard work and effort that the doctors and researchers have put forth. The research was led by COL David McLeod, (Ret), MD, CPDR Director and Professor at Uniformed Services University (USU) and by Shiv Srivastava, PhD, Co-Director and Professor at USU.

1. Distinguing features of ERG oncoprotein expression among matched cohorts of African-American and Caucasian-American prostate cancer patients
Philip Rosen, David Pfister, Denise Young, Gyorgy Petrovics, Yongmei Chen, Albert Dobi, David McLeod, Shiv Srivastava, Isabell Sesterhenn

2. Age-associated gene-expression signatures in non-familial prostate cancer
Travis Allemang, Shashwat Sharad, Gyorgy Petrovics, Jennifer Cullen, Isabell Sesterhenn, David McLeod, Stephen Brassell, Shiv Srivastava, Albert Dobi

3. ERG oncoprotein expression in localized prostate cancer in Japanese population
Takahiro Inoue, Takehiko Segawa, Atushi Maeno, Shusuke Akamatsu, Takeshi Yoshikawa, Yousuke Shimizu, Kamba Tomomi, Koji Yoshimura, Albert Dobi, Shiv Srivastava, Osamu Ogawa

4. "Very low risk" appears to be a valid novel risk stratification for localized prostate cancer
Timothy Tausch, Jennifer Cullen, Yongmei Chen, Timothy Brand

5. The roles of race/ethnicity and body mass index on prostate cancer biochemical recurrence and all-cause mortality
Jennifer Cullen, Anjali Srivastava, Monica Colombo, Stephen Brassell, Yongmei Chen, Timothy Brand, James L'Esperance, Christopher Porter, Joseph Sterbis, David McLeod

6. Sipuleucel-T in African Americans: a subgroup analysis of three phase 3 trials of sipuleucel-T in metastatic castrate resistant prostate cancer
David G. McLeod, David I. Quinn, Jennifer Cullen, James B. Whitmore

7. Immunohistochemical expression of ERG oncoprotein is associated with development of local recurrence and prostate cancer-specific death in men treated with radical prostatectomy
Elysia Sophia Spencer, Richard Johnston, Dan Lewinshtein, Ryan R. Gordon, Sandra Koo, Albert Dobi, David G. McLeod, Funda Vakar-Lopez, Shiv Srivastava, Martin Gleave, Peter Nelson, Christopher Porter

8. Comprehensive analysis of the TMPRSS2-ERG translocation during prostate cancer progression
Shyh-Han Tan, Christian Ruiz, Martin Braun, Veit Scheble, T Zellweger, CA Rentsch, A Bachmann, Albert Dobi, Sven Perner, Isabell Sesterhenn, Shiv Srivastava, L Bubendor

9. Androgen receptor (AR) degradation is controlled by the co-operation of PMEPA1 and the E3 ubiquitin ligase NEDD4-1
Hua Li, Albert Dobi, Shiv Srivastava

10. Alkaline phosphatase kinetics and the risk of bone metastases in men undergoing androgen deprivation therapy
Inger Rosner, Adam Metwalli, Stephen Brassell, Jennifer Cullen, Yongmei Chen, David McLeod

11. Epigenetic regulation of the androgen receptor regulator PMEPA1 in prostate cancer cells
Shashwat Sharad, Hua Li, Michael Haffner, Srinivasan Yegnasubramanian, Gyorgy Petrovics, Shiv Srivastava, Albert Dobi

The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Center, the Basic Science Research Program and the National Multicenter Prostate Cancer Database– and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRNMMC US TOO! organization and through a heavy schedule of health fairs in which it participates.